Skip to main content

Table 3 Randomized acute ischemic syndrome trials for intravenous glycoprotein IIb/IIIa blockade

From: Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Trial (number of patients) Agent tested Entry criteria Primary endpoints
PURSUIT (10,948) Eptifibatide CP at rest or minimal exertion within Death, and non-fatal MI, at 30 days
   24 hours and either ischemic ECG  
   changes* or CK-MB elevations  
PRISM-PLUS (1915) Tirofiban CP at rest or minimal exertion within Death, MI, or refractory ischemia, at 7 days
   12 hours and either ischemic ECG  
   changes* or CK-MB elevations  
PRISM (3232) Tirofiban CP at rest or minimal exertion within Death, MI or refractory ischemia, at 48 hours
   24 hours and ischemic ECG changes*  
   or CK-MB elevations or history of CAD or  
   positive stress test  
PARAGON A (2282) Lamifiban CP at rest within 12 hours and ischemic Death, and non-fatal MI, at 30 days
   ECG changes*  
PARAGON B (5225) Lamifiban Patients within 12 hours of symptoms of The composite incidence of death, MI, or SRI, at
   acute myocardial ischemia and ECG changes* 30 days
GUSTO IV-ACS (7800) Abciximab ACS within last 24 hours; > 5 min anginal All-cause mortality, composite endpoint of death,
   symptoms at rest, and either + troponin I/T, or MI, at 30 days
   or ST depression ≥ 0.5 mm  
  1. ACS, Acute coronary syndromes; CAD, coronary artery disease; CK-MB, creatine kinase MB isoenzyme; CP, Chest pain; ECG, electrocardiogram; MI, myocardial infarction; SRI, severe refractory ischemia. * ST depression, T inversion or transient ST elevation.